4.7 Article

Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States

期刊

KIDNEY INTERNATIONAL
卷 99, 期 3, 页码 686-695

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2020.12.019

关键词

albuminuria; blood pressure; clinical practice guidelines; chronic kidney disease; hypertension

资金

  1. National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) [T32 HL007024]
  2. NIH/National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK106515]
  3. NIH/NHLBI [K24 HL152440]

向作者/读者索取更多资源

The 2021 KDIGO guideline recommends a target systolic blood pressure under 120 mmHg for adults with CKD, with a focus on ACEi/ARB use for those with albuminuria; the study found that more patients in the United States meet the criteria for blood pressure lowering according to the new guideline.
The 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (CKD) recommends a target systolic blood pressure under 120 mmHg based on standardized office blood pressure measurement. Here, we examined the potential implications of this new guideline for blood pressure lowering with antihypertensive medication among adults in the United States with CKD compared to the 2012 KDIGO guideline (target blood pressure 130/80 mmHg or under with albuminuria or 140/90 mmHg or under without albuminuria) and the 2017 American College of Cardiology/American Heart Association (target blood pressure under 130/80 mmHg) guideline. Additionally, we determined implications of the 2021 KDIGO guideline for angiotensin converting enzyme inhibitor (ACEi) or angiotensin IIreceptor blocker (ARB) use for those with albuminuria (recommended at systolic blood pressure of 120 mmHg or over) compared to the 2012 KDIGO guideline (recommended at blood pressures over 130/80 mmHg). Data were analyzed from 1,699 adults with CKD (estimated glomerular filtration rate 15-59 ml/min/1.73m(2) or a urinary albumin-to-creatinine ratio of 30 mg/g or more) in the 2015-2018 National Health and Nutrition Examination Survey and averaged up to three standardized blood pressure measurements. Among adults with CKD, 69.5% were eligible for blood pressure lowering according to the 2021 KDIGO guideline, compared with 49.8% as per 2012 KDIGO or 55.6% as per 2017 American College of Cardiology/American Heart Association guidelines. Among those with albuminuria, 78.2% were eligible for ACEi/ARB use by the 2021 KDIGO guideline compared with 71.0% by the 2012 KDIGO guideline. However, only 39.1% were taking an ACEi/ARB. Thus, our findings highlight opportunities to improve blood pressure management and reduce cardiovascular risk among adults in the United States with CKD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据